| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 10,785 | 13,250 | 38,701 | NaN |
| Cost of product revenue | 1,329 | 1,594 | 4,980 | NaN |
| Axpaxli | 42,460 | 26,716 | 92,893 | NaN |
| Direct program expenses, axpaxli for npdr | NaN | 4,804 | NaN | NaN |
| Direct program expenses, other clinical and preclinical programs | 758 | 275 | 3,307 | NaN |
| Unallocated expenses, personnel costs | 12,976 | 11,430 | 27,825 | NaN |
| Unallocated expenses, all other costs | 1,809 | 1,541 | 5,986 | NaN |
| Selling & marketing | 14,075 | 11,538 | 36,972 | NaN |
| General & administrative | 11,606 | 10,513 | 26,864 | NaN |
| Facilities | 2,270 | 1,993 | 5,230 | NaN |
| Stock-based compensation | 15,582 | 11,359 | 31,825 | NaN |
| Depreciation | 1,260 | 1,247 | 3,076 | NaN |
| Interest income | 6,050 | 7,343 | 11,012 | NaN |
| Interest expense | 2,777 | 2,832 | 9,003 | NaN |
| Other non-operating items | 1,455 | 595 | -3,037 | NaN |
| Net loss | -88,612 | -64,654 | -69,418 | -131,867 |
| Stock-based compensation expense | 15,582 | 11,359 | 11,691 | 20,134 |
| Non-cash interest expense | 1,381 | 495 | 758 | 2,144 |
| Change in fair value of derivative liabilities | 1,455 | 595 | -1,447 | -1,619 |
| Depreciation and amortization expense | 1,283 | 1,247 | 1,069 | 2,007 |
| Loss on disposal of items of property and equipment | -4,866 | 0 | 0 | 29 |
| Accounts receivable, net | -6,303 | -118 | 356 | -1,976 |
| Prepaid expenses and other current assets | 357 | 2,903 | -522 | -4,983 |
| Inventory | 173 | 76 | 449 | -1 |
| Accounts payable | 3,719 | -1,353 | -1,272 | 1,738 |
| Deferred revenue | NaN | 0 | 0 | -128 |
| Operating lease assets | 1,857 | -696 | -549 | -62 |
| Accrued expenses | -8,441 | 2,176 | 5,376 | -2,304 |
| Operating lease liabilities | 1,768 | -759 | -642 | -245 |
| Net cash used in operating activities | -65,993 | -54,249 | -50,725 | -99,909 |
| Proceeds from sales of property and equipment | NaN | 0 | 0 | 130 |
| Purchases of property and equipment | 4,662 | 2,839 | 5,993 | 3,178 |
| Net cash used in investing activities | -4,662 | -2,839 | -5,993 | -3,048 |
| Proceeds from issuance of common stock pursuant to employee stock purchase plan | NaN | 879 | 0 | 713 |
| Proceeds from issuance of common stock upon public offering, net of issuance costs | NaN | 445,560 | 0 | 94,025 |
| Proceeds from exercise of stock options | 294 | 2,937 | 10,356 | 7,251 |
| Net cash provided by financing activities | 294 | 449,376 | 10,356 | 101,989 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -70,361 | 392,288 | -46,362 | -968 |
| Cash, cash equivalents and restricted cash at beginning of period | 738,674 | 346,386 | 393,716 | NaN |
| Cash, cash equivalents and restricted cash at end of period | 668,313 | 738,674 | 346,386 | NaN |
OCULAR THERAPEUTIX, INC (OCUL)
OCULAR THERAPEUTIX, INC (OCUL)